Literature DB >> 18848996

Large-scale Epstein-Barr virus EBNA1 protein purification.

Sarah J Duellman1, Richard R Burgess.   

Abstract

The protein-DNA and protein-protein interactions of Epstein-Barr virus nuclear antigen 1 (EBNA1) are known to play an important role in the many functions of this viral protein. Large quantities of pure EBNA1 protein would be useful in biochemical assays to elucidate such interactions. In particular, the crystal structure of the full-length protein would be important to show possible regions of interaction and/or post-translational modification. Recently, we described a novel approach to overexpress and purify EBNA1 from Escherichia coli; however, it is not ideal for large-scale production of EBNA1. We were able to optimize this protocol by (1) adding a polyethyleneimine precipitation step prior to Ni-NTA chromatography to reduce complexity of the sample and remove nucleic acid, (2) optimizing the Ni-NTA gradient to further separate EBNA1 from impurities, and (3) concluding with a MonoS cation-exchange chromatography step to further purify and concentrate EBNA1. We were able to recover 10-mg quantities of pure EBNA1 protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848996      PMCID: PMC2744152          DOI: 10.1016/j.pep.2008.09.012

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  13 in total

Review 1.  EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus.

Authors:  E R Leight; B Sugden
Journal:  Rev Med Virol       Date:  2000 Mar-Apr       Impact factor: 6.989

2.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

3.  Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA.

Authors:  A Bochkarev; J A Barwell; R A Pfuetzner; E Bochkareva; L Frappier; A M Edwards
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection.

Authors:  B Sugden; N Warren
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

Review 6.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1.

Authors:  A Bochkarev; J A Barwell; R A Pfuetzner; W Furey; A M Edwards; L Frappier
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

8.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene.

Authors:  T A Gahn; B Sugden
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

Authors:  J Yates; N Warren; D Reisman; B Sugden
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 10.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

View more
  1 in total

1.  Isolation and characterization of the DNA and protein binding activities of adenovirus core protein V.

Authors:  Jimena Pérez-Vargas; Robert C Vaughan; Carolyn Houser; Kathryn M Hastie; C Cheng Kao; Glen R Nemerow
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.